The Annual FDA/PhUSE Computational Science Symposium, to be held on March 18th and 19th 2013 in
Silver Spring, Maryland, provides the premier forum for industry and FDA to collaborate in the realm of
computational science.
PhUSE, an independent, non‐profit community of professionals focused around the advancement of clinical
information is proud to co‐sponsor, along with The Food and Drug Administration, the Annual FDA/PhUSE
Computational Science Symposium, to be held on March 18th and 19th 2013 in Silver Spring, Maryland, USA.
The symposium is an opportunity for FDA, the pharmaceutical industry, academia, and other computational
science stakeholders to meet in a collaborative environment.
“The symposium provides a platform for FDA and industry to collaborate with the goal of closing some of the
gaps we face in delivering information to the FDA and solving the challenges FDA deals with during their
review cycle,” says Chris Decker, PhUSE FDA Liaison and Vice President, Life Sciences Practice at d‐Wise.
A vital part of the stakeholder collaboration resulted from the creation of working groups at the annual
symposium in 2012. The working group areas of focus are: Data Quality, Data Standards, Standard Scripts,
Non‐clinical. The 2013 Symposium will provide a venue for these groups to continue their collaborative efforts,
as well as to share the exciting progress that they have made in 2012. Additional projects are being formed to
address increasing challenges to the access and review of data identified since the previous meeting.
Participants are encouraged to submit abstracts for a poster session at the Symposium. Abstracts are due by
January 31st 2013.
The Symposium will be held at the Silver Spring Civic Building at Veterans Plaza.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.